{"id":59994,"date":"2014-07-27T10:50:25","date_gmt":"2014-07-27T10:50:25","guid":{"rendered":"https:\/\/leitat.org\/blog\/toxab\/"},"modified":"2025-02-24T20:33:53","modified_gmt":"2025-02-24T20:33:53","slug":"toxab","status":"publish","type":"post","link":"https:\/\/leitat.org\/en\/blog\/toxab\/","title":{"rendered":"TOXAB"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"59994\" class=\"elementor elementor-59994 elementor-8053\" data-elementor-post-type=\"post\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-gblobya elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"gblobya\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-zeldwwl\" data-id=\"zeldwwl\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-vshsdmo elementor-widget elementor-widget-heading\" data-id=\"vshsdmo\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h4 class=\"elementor-heading-title elementor-size-default\">TOXAB<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-thcwoms elementor-widget elementor-widget-text-editor\" data-id=\"thcwoms\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h5>Development of Novel, Safe and Affordable Cytotoxic Antibodies for the Treatment of Cancer<\/h5>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-etdgsuv elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"etdgsuv\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-lhcmoav\" data-id=\"lhcmoav\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-afwnmms elementor-widget elementor-widget-text-editor\" data-id=\"afwnmms\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>ABSTRACT<\/strong><\/p><p style=\"text-align: justify;\"><span id=\"result_box\" class=\"\" lang=\"en\"><span title=\"El proyecto de investigaci\u00f3n aplicada ToxAb tiene por objetivo principal generar una ventaja competitiva en el \u00e1rea de la terapia oncol\u00f3gica mediante la validaci\u00f3n y el uso de la tecnolog\u00eda de conjugaci\u00f3n de agentes citot\u00f3xicos y material g\u00e9nico (PPRHs) a anticuerpos monoclonales.\">The main objective of the ToxAb applied research project is to generate a competitive advantage in the field of cancer therapy by validating and using the technology of conjugation of cytotoxic agents and gene material (PPRHs) to monoclonal antibodies. <\/span><span title=\"Por tanto, el proyecto combina el potencial de tres l\u00edneas de investigaci\u00f3n punteras: \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\">Therefore, the project combines the potential of three leading lines of research:<\/span><\/span><\/p><ul style=\"text-align: justify;\"><li><span id=\"result_box\" class=\"\" lang=\"en\"><span title=\"La utilizaci\u00f3n de nuevos anticuerpos monoclonales desarrollados por LEITAT contra dianas implicadas en el desarrollo tumoral de la familia del epidermal growth factor \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\">The use of new monoclonal antibodies developed by LEITAT against targets involved in the tumor development of the epidermal growth factor family<\/span><\/span><\/li><li><span id=\"result_box\" class=\"\" lang=\"en\"><span title=\"receptor (Her1\/EGFR i Her2\/ErbB2) \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\">Receptor (Her1 \/ EGFR and Her2 \/ ErbB2)<\/span><\/span><\/li><li><span id=\"result_box\" class=\"\" lang=\"en\"><span title=\"El uso de una tecnolog\u00eda puntera en la conjugaci\u00f3n de citot\u00f3xicos desarrollado internacionalmente por la empresa ProteoDesign, \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\">The use of a leading technology in the conjugation of cytotoxics developed internationally by the company ProteoDesign<\/span><\/span><\/li><li><span id=\"result_box\" class=\"\" lang=\"en\"> <span title=\"La utilizaci\u00f3n de material g\u00e9nico basado en la tecnolog\u00eda del silenciamiento por PPRHs desarrollado y validado por LEITAT dirigido contra dianas ampliamente validadas a nivel de terapia antitumoral. \">The use of genetic material based on the silencing technology by PPRHs developed and validated by LEITAT directed against targets widely validated at the level of antitumor therapy.<\/span><\/span><\/li><\/ul><p style=\"text-align: justify;\"><span id=\"result_box\" class=\"\" lang=\"en\"><span title=\"El proyecto se inscribe en el entorno de un nuevo paradigma por el que actualmente apuestan todas las grandes empresas farmac\u00e9uticas a nivel internacional: los ADC.\">The project is part of the framework of a new paradigm for which all the major pharmaceutical companies at the international level: the ADCs. <\/span><span title=\"Adicionalmente, combina el potencial de investigaci\u00f3n llevada a cabo en centros de investigaci\u00f3n espa\u00f1oles y universidades norteamericanas (Universidad de Princeton y Universidad Rockefeller) a trav\u00e9s de dos entidades espa\u00f1olas. \">Additionally, it combines the research potential carried out in Spanish research centers and North American universities (Princeton University and Rockefeller University) through two Spanish entities.<\/span><\/span><\/p><p style=\"text-align: justify;\"><span id=\"result_box\" class=\"\" lang=\"en\"><span title=\"La colaboraci\u00f3n se ha establecido entre un a spin-off de reciente creaci\u00f3n (ProteoDesign SL) que ha desarrollado una tecnolog\u00eda revolucionaria de conjugaci\u00f3n, con un Centro Tecnol\u00f3gico (LEITAT) con amplia experiencia en el campo de los anticuerpos y en la caracterizaci\u00f3n funcional de nuevos\">The collaboration has been established between a newly created spin-off (ProteoDesign SL) that has developed a revolutionary technology of conjugation, with a Technological Center (LEITAT) with extensive experience in the field of antibodies and in the functional characterization of new <\/span><span title=\"agent es antitumorales.\">Agent is antitumor. <\/span><span title=\"El proyecto ToxAb permitir\u00e1 desarrollar nuevos ADCs con gran valor a\u00f1adido y mejor \u00edndice terap\u00e9utico que los utilizados actualmente. \">The ToxAb project will allow the development of new ADCs with high added value and a better therapeutic index than those currently used.<\/span><\/span><\/p><p style=\"text-align: justify;\"><span id=\"result_box\" class=\"\" lang=\"en\"><span title=\"Una de las tecnolog\u00edas de la Biomed divisi\u00f3n del Centro Tecnol\u00f3gico Leitat est\u00e1 basada en su amplia experiencia en la generaci\u00f3n y desarrollo de anticuerpos monoclonales para usos diagn\u00f3sticos y terap\u00e9uticos;\">One of the technologies of the Biomed division of the Leitat Technology Center is based on its extensive experience in the generation and development of monoclonal antibodies for diagnostic and therapeutic uses; <\/span><span title=\"as\u00ed como la capacidad de an\u00e1lisis de la eficacia terap\u00e9utica de nuevos f\u00e1rmacos en una gran variedad de modelos celulares in vitro y de modelos de crecimiento de tumor en animales. \">As well as the ability to analyze the therapeutic efficacy of novel drugs in a variety of in vitro cell models and animal tumor growth models.<\/span><\/span><\/p><p style=\"text-align: justify;\"><span id=\"result_box\" class=\"\" lang=\"en\"><span title=\"Actualmente Leitat ha generado nuevos anticuerpos monoclonales para aplicaci\u00f3n terap\u00e9utica contra receptores transmembranales expresados en la superficie de c\u00e9lulas tumorales.\">Currently Leitat has generated new monoclonal antibodies for therapeutic application against transmembrane receptors expressed on the surface of tumor cells. <\/span><span title=\"La particularidad de estos anticuerpos reside en su doble especificidad ya que reconocen un ep\u00edtopo com\u00fan en Her1 y en Her2.\">The particularity of these antibodies lies in their double specificity since they recognize a common epitope in Her1 and Her2. <\/span><span title=\"Si bien existen anticuerpos en el mercado contra Her1 (Erbitux y Vectibix) y contra Her2 (Herceptin y Perjeta), hasta la fecha los \u00fanicos inhibidores duales contra Her1 y Her2 son mol\u00e9culas qu\u00edmicas de bajo peso molecular (lapatinib, neratinib, y afatinib).\">Although antibodies against Her1 (Erbitux and Vectibix) and against Her2 (Herceptin and Perjeta) exist to date, the only dual inhibitors against Her1 and Her2 are low molecular weight chemical molecules (lapatinib, neratinib, and afatinib). <\/span><span title=\"Estas mol\u00e9culas y sus buenos resultados terap\u00e9uticos en pacientes de distintos tipos tumorales abren la puerta a la aproximaci\u00f3n dual tambi\u00e9n en monoclonales.\">These molecules and their good therapeutic results in patients of different tumor types open the door to the dual approach also in monoclonal ones. <\/span><span title=\"En este sentido, los nuevos anticuerpos generados por LEITAT representan un reflejo de estas necesidades.\">In this sense, the new antibodies generated by LEITAT represent a reflection of these needs. <\/span><span title=\"Adicionalmente, cabe considerar los efectos secundarios que han mostrado los mAbs contra Her1 (rash d\u00e9rmico) o los mAbs contra Her2 (problemas cardiovasculares) y que no se han descrito de manera cruzada.\">Additionally, the side effects reported by mAbs against Her1 (dermal rash) or mAbs against Her2 (cardiovascular problems) and which have not been described in a cross-over manner may be considered. <\/span><span title=\"La especificidad dual de los nuevos mAbs permite suponer que el ep\u00edtopo reconocido no participa en ninguna de las patolog\u00edas y consecuentemente podr\u00edan ser mejor tolerados por los pacientes. \">The dual specificity of the new mAbs allows us to assume that the recognized epitope does not participate in any of the pathologies and consequently could be better tolerated by the patients.<\/span><\/span><\/p><p style=\"text-align: justify;\"><span id=\"result_box\" class=\"\" lang=\"en\"><span title=\"Adem\u00e1s, recientemente el grupo de investigaci\u00f3n de la Biomed Division de Leitat ha publicado el uso de hairpins de DNA (PPRH) contra survivina como agente de terapia g\u00e9nica para tumores de pr\u00f3stata, siendo esta estrategia extensible tambi\u00e9n a otros tumores. \">In addition, recently the Leitat Biomed Division research group has published the use of DNA hairpins (PPRH) against survivin as a gene therapy agent for prostate tumors, this strategy being also extended to other tumors.<\/span><\/span><\/p><p style=\"text-align: justify;\"><span id=\"result_box\" class=\"\" lang=\"en\"><span title=\"La uni\u00f3n de los nuevos PPRH de Leitat contra survivina (para c\u00e1ncer de mama y colon) a los nuevos anticuerpos anti-Her1\/Her2 de Leitat mediante la innovadora tecnolog\u00eda de Proteo Design justifica el car\u00e1cter innovador del presente proyecto ToxAb.\">The combination of the new Leitat PPRH against survivin (for breast and colon cancer) to the new Leitat anti-Her1 \/ Her2 antibodies using the innovative Proteo Design technology justifies the innovative character of this ToxAb project. <\/span><span title=\"Adem\u00e1s, el proyecto se complementa tambi\u00e9n con la uni\u00f3n de mol\u00e9culas citot\u00f3xicas a los mismos anticuerpos.\">In addition, the project is also complemented with the binding of cytotoxic molecules to the same antibodies. <\/span><span title=\"Finalmente, el proyecto contempla el an\u00e1lisis de la actividad terap\u00e9utica anti-c\u00e1ncer de los productos generados en los modelos celulares y en los modelos decrecimiento de tumor en ratones que dispone el centro Leitat.\">Finally, the project contemplates the analysis of the anti-cancer therapeutic activity of the products generated in the cellular models and in the tumor-reduction models in mice provided by the Leitat center.<\/span><\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-ovoaqdr elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"ovoaqdr\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-frswwcq\" data-id=\"frswwcq\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-zzzimem elementor-widget elementor-widget-text-editor\" data-id=\"zzzimem\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Project Budget: <\/strong>276.418,39 \u20ac<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-mgtzdcp\" data-id=\"mgtzdcp\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-fsevrdc elementor-widget elementor-widget-text-editor\" data-id=\"fsevrdc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Financial Framework:<\/strong> RETOS COLABORACI\u00d3N<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-xracaun elementor-widget elementor-widget-text-editor\" data-id=\"xracaun\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Contract number:<\/strong> RTC-2014-1685-1<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-matymku\" data-id=\"matymku\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-ueaiuzb elementor-widget elementor-widget-text-editor\" data-id=\"ueaiuzb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Start Date:<\/strong> 27\/01\/2014<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-nmeirqs elementor-widget elementor-widget-text-editor\" data-id=\"nmeirqs\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>End Date:<\/strong> 31\/12\/2017<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-brhhwec elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"brhhwec\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-dkgkirt\" data-id=\"dkgkirt\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-wwgylxb elementor-widget elementor-widget-text-editor\" data-id=\"wwgylxb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Partners:<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-izwwfvk elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"izwwfvk\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-uphvzxz\" data-id=\"uphvzxz\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-agcqcrg elementor-widget elementor-widget-image-gallery\" data-id=\"agcqcrg\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image-gallery.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<div class=\"elementor-image-gallery\">\n\t\t\t<div id='gallery-1' class='gallery galleryid-59994 gallery-columns-4 gallery-size-excerpt-thumbnail'><figure class='gallery-item'>\n\t\t\t<div class='gallery-icon landscape'>\n\t\t\t\t<img fetchpriority=\"high\" width=\"600\" height=\"480\" src=\"https:\/\/leitat.org\/wp-content\/uploads\/2017\/08\/Proteo-Design.png\" class=\"attachment-excerpt-thumbnail size-excerpt-thumbnail\" alt=\"\" aria-describedby=\"gallery-1-48029\" decoding=\"async\" srcset=\"https:\/\/leitat.org\/wp-content\/uploads\/2017\/08\/Proteo-Design.png 600w, https:\/\/leitat.org\/wp-content\/uploads\/2017\/08\/Proteo-Design-300x240.png 300w\" sizes=\"(max-width: 600px) 100vw, 600px\" \/>\n\t\t\t<\/div>\n\t\t\t\t<figcaption class='wp-caption-text gallery-caption' id='gallery-1-48029'>\n\t\t\t\tCoordinator\n\t\t\t\t<\/figcaption><\/figure><figure class='gallery-item'>\n\t\t\t<div class='gallery-icon portrait'>\n\t\t\t\t<img width=\"400\" height=\"420\" src=\"https:\/\/leitat.org\/wp-content\/uploads\/2017\/08\/LEITAT-400x420-1.png\" class=\"attachment-excerpt-thumbnail size-excerpt-thumbnail\" alt=\"\" decoding=\"async\" srcset=\"https:\/\/leitat.org\/wp-content\/uploads\/2017\/08\/LEITAT-400x420-1.png 400w, https:\/\/leitat.org\/wp-content\/uploads\/2017\/08\/LEITAT-400x420-1-286x300.png 286w\" sizes=\"(max-width: 400px) 100vw, 400px\" \/>\n\t\t\t<\/div><\/figure>\n\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-rguknwo elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"rguknwo\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-akeocxa\" data-id=\"akeocxa\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-kkwiaxq elementor-widget elementor-widget-text-editor\" data-id=\"kkwiaxq\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Contact Manager:<\/strong> <a href=\"mailto:snieva@leitat.org\">S. Nieva<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-gqoskau elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"gqoskau\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-ofqmqzu\" data-id=\"ofqmqzu\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-mnywupb elementor-widget elementor-widget-image\" data-id=\"mnywupb\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"800\" height=\"155\" src=\"https:\/\/leitat.org\/wp-content\/uploads\/2019\/04\/MCIU_Gob_Web_AEI-1024x199.jpg\" class=\"attachment-large size-large wp-image-51091\" alt=\"\" srcset=\"https:\/\/leitat.org\/wp-content\/uploads\/2019\/04\/MCIU_Gob_Web_AEI-1024x199.jpg 1024w, https:\/\/leitat.org\/wp-content\/uploads\/2019\/04\/MCIU_Gob_Web_AEI-300x58.jpg 300w, https:\/\/leitat.org\/wp-content\/uploads\/2019\/04\/MCIU_Gob_Web_AEI-768x149.jpg 768w, https:\/\/leitat.org\/wp-content\/uploads\/2019\/04\/MCIU_Gob_Web_AEI-1536x298.jpg 1536w, https:\/\/leitat.org\/wp-content\/uploads\/2019\/04\/MCIU_Gob_Web_AEI.jpg 2048w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-45828bd elementor-widget elementor-widget-image\" data-id=\"45828bd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"535\" height=\"142\" src=\"https:\/\/leitat.org\/wp-content\/uploads\/2016\/10\/LOGO_FEDER_es-670x300-1.png\" class=\"attachment-large size-large wp-image-55247\" alt=\"\" srcset=\"https:\/\/leitat.org\/wp-content\/uploads\/2016\/10\/LOGO_FEDER_es-670x300-1.png 535w, https:\/\/leitat.org\/wp-content\/uploads\/2016\/10\/LOGO_FEDER_es-670x300-1-300x80.png 300w\" sizes=\"(max-width: 535px) 100vw, 535px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-66 elementor-top-column elementor-element elementor-element-ddzshwg\" data-id=\"ddzshwg\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-odshnwv elementor-widget elementor-widget-text-editor\" data-id=\"odshnwv\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Financiado por: FEDER\/Ministerio de Ciencia,Innovaci\u00f3n y Universidades \u2013 Agencia Estatal de Investigaci\u00f3n\/_Proyecto RTC-2014-1685-1<\/p><p>Objetivo Tem\u00e1tico del Programa Operativo: Promover el desarrollo tecnol\u00f3gico, la innovaci\u00f3n y una investigaci\u00f3n de calidad.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>TOXAB Development of Novel, Safe and Affordable Cytotoxic Antibodies for the Treatment of Cancer ABSTRACT The main objective of the ToxAb applied research project is to generate a competitive advantage in the field of cancer therapy by validating and using the technology of conjugation of cytotoxic agents and gene material (PPRHs) to monoclonal antibodies. Therefore, [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":47191,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[142],"tags":[112],"class_list":["post-59994","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health-technologies-en","tag-projects"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TOXAB - Leitat Technological Center<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TOXAB - Leitat Technological Center\" \/>\n<meta property=\"og:description\" content=\"TOXAB Development of Novel, Safe and Affordable Cytotoxic Antibodies for the Treatment of Cancer ABSTRACT The main objective of the ToxAb applied research project is to generate a competitive advantage in the field of cancer therapy by validating and using the technology of conjugation of cytotoxic agents and gene material (PPRHs) to monoclonal antibodies. Therefore, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/leitat.org\/en\/blog\/toxab\/\" \/>\n<meta property=\"og:site_name\" content=\"Leitat Technological Center\" \/>\n<meta property=\"article:published_time\" content=\"2014-07-27T10:50:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-24T20:33:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/leitat.org\/wp-content\/uploads\/2017\/07\/Toxcab.png\" \/>\n\t<meta property=\"og:image:width\" content=\"179\" \/>\n\t<meta property=\"og:image:height\" content=\"180\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Comunicaci\u00f3n Leitat\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Comunicaci\u00f3n Leitat\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/leitat.org\/en\/blog\/toxab\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/leitat.org\/en\/blog\/toxab\/\"},\"author\":{\"name\":\"Comunicaci\u00f3n Leitat\",\"@id\":\"https:\/\/leitat.org\/en\/#\/schema\/person\/ca8dc97489cd821df9e0c42930e89131\"},\"headline\":\"TOXAB\",\"datePublished\":\"2014-07-27T10:50:25+00:00\",\"dateModified\":\"2025-02-24T20:33:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/leitat.org\/en\/blog\/toxab\/\"},\"wordCount\":667,\"publisher\":{\"@id\":\"https:\/\/leitat.org\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/leitat.org\/en\/blog\/toxab\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2017\/07\/Toxcab.png\",\"keywords\":[\"Projects\"],\"articleSection\":[\"Health technologies\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/leitat.org\/en\/blog\/toxab\/\",\"url\":\"https:\/\/leitat.org\/en\/blog\/toxab\/\",\"name\":\"TOXAB - Leitat Technological Center\",\"isPartOf\":{\"@id\":\"https:\/\/leitat.org\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/leitat.org\/en\/blog\/toxab\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/leitat.org\/en\/blog\/toxab\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2017\/07\/Toxcab.png\",\"datePublished\":\"2014-07-27T10:50:25+00:00\",\"dateModified\":\"2025-02-24T20:33:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/leitat.org\/en\/blog\/toxab\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/leitat.org\/en\/blog\/toxab\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/leitat.org\/en\/blog\/toxab\/#primaryimage\",\"url\":\"https:\/\/leitat.org\/wp-content\/uploads\/2017\/07\/Toxcab.png\",\"contentUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2017\/07\/Toxcab.png\",\"width\":179,\"height\":180},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/leitat.org\/en\/blog\/toxab\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"HOME\",\"item\":\"https:\/\/leitat.org\/en\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Health technologies\",\"item\":\"https:\/\/leitat.org\/en\/blog\/category\/health-technologies-en\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"TOXAB\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/leitat.org\/en\/#website\",\"url\":\"https:\/\/leitat.org\/en\/\",\"name\":\"Leitat Technological Center\",\"description\":\"Managing Technologies\",\"publisher\":{\"@id\":\"https:\/\/leitat.org\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/leitat.org\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/leitat.org\/en\/#organization\",\"name\":\"Leitat Technological Center\",\"url\":\"https:\/\/leitat.org\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/leitat.org\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg\",\"contentUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg\",\"width\":226,\"height\":78,\"caption\":\"Leitat Technological Center\"},\"image\":{\"@id\":\"https:\/\/leitat.org\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/leitat.org\/en\/#\/schema\/person\/ca8dc97489cd821df9e0c42930e89131\",\"name\":\"Comunicaci\u00f3n Leitat\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g\",\"caption\":\"Comunicaci\u00f3n Leitat\"},\"sameAs\":[\"https:\/\/leitat.org\"],\"url\":\"https:\/\/leitat.org\/en\/blog\/author\/comunica-wp\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TOXAB - Leitat Technological Center","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"TOXAB - Leitat Technological Center","og_description":"TOXAB Development of Novel, Safe and Affordable Cytotoxic Antibodies for the Treatment of Cancer ABSTRACT The main objective of the ToxAb applied research project is to generate a competitive advantage in the field of cancer therapy by validating and using the technology of conjugation of cytotoxic agents and gene material (PPRHs) to monoclonal antibodies. Therefore, [&hellip;]","og_url":"https:\/\/leitat.org\/en\/blog\/toxab\/","og_site_name":"Leitat Technological Center","article_published_time":"2014-07-27T10:50:25+00:00","article_modified_time":"2025-02-24T20:33:53+00:00","og_image":[{"width":179,"height":180,"url":"https:\/\/leitat.org\/wp-content\/uploads\/2017\/07\/Toxcab.png","type":"image\/png"}],"author":"Comunicaci\u00f3n Leitat","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Comunicaci\u00f3n Leitat","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/leitat.org\/en\/blog\/toxab\/#article","isPartOf":{"@id":"https:\/\/leitat.org\/en\/blog\/toxab\/"},"author":{"name":"Comunicaci\u00f3n Leitat","@id":"https:\/\/leitat.org\/en\/#\/schema\/person\/ca8dc97489cd821df9e0c42930e89131"},"headline":"TOXAB","datePublished":"2014-07-27T10:50:25+00:00","dateModified":"2025-02-24T20:33:53+00:00","mainEntityOfPage":{"@id":"https:\/\/leitat.org\/en\/blog\/toxab\/"},"wordCount":667,"publisher":{"@id":"https:\/\/leitat.org\/en\/#organization"},"image":{"@id":"https:\/\/leitat.org\/en\/blog\/toxab\/#primaryimage"},"thumbnailUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2017\/07\/Toxcab.png","keywords":["Projects"],"articleSection":["Health technologies"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/leitat.org\/en\/blog\/toxab\/","url":"https:\/\/leitat.org\/en\/blog\/toxab\/","name":"TOXAB - Leitat Technological Center","isPartOf":{"@id":"https:\/\/leitat.org\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/leitat.org\/en\/blog\/toxab\/#primaryimage"},"image":{"@id":"https:\/\/leitat.org\/en\/blog\/toxab\/#primaryimage"},"thumbnailUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2017\/07\/Toxcab.png","datePublished":"2014-07-27T10:50:25+00:00","dateModified":"2025-02-24T20:33:53+00:00","breadcrumb":{"@id":"https:\/\/leitat.org\/en\/blog\/toxab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/leitat.org\/en\/blog\/toxab\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/leitat.org\/en\/blog\/toxab\/#primaryimage","url":"https:\/\/leitat.org\/wp-content\/uploads\/2017\/07\/Toxcab.png","contentUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2017\/07\/Toxcab.png","width":179,"height":180},{"@type":"BreadcrumbList","@id":"https:\/\/leitat.org\/en\/blog\/toxab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"HOME","item":"https:\/\/leitat.org\/en\/home\/"},{"@type":"ListItem","position":2,"name":"Health technologies","item":"https:\/\/leitat.org\/en\/blog\/category\/health-technologies-en\/"},{"@type":"ListItem","position":3,"name":"TOXAB"}]},{"@type":"WebSite","@id":"https:\/\/leitat.org\/en\/#website","url":"https:\/\/leitat.org\/en\/","name":"Leitat Technological Center","description":"Managing Technologies","publisher":{"@id":"https:\/\/leitat.org\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/leitat.org\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/leitat.org\/en\/#organization","name":"Leitat Technological Center","url":"https:\/\/leitat.org\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/leitat.org\/en\/#\/schema\/logo\/image\/","url":"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg","contentUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg","width":226,"height":78,"caption":"Leitat Technological Center"},"image":{"@id":"https:\/\/leitat.org\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/leitat.org\/en\/#\/schema\/person\/ca8dc97489cd821df9e0c42930e89131","name":"Comunicaci\u00f3n Leitat","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g","caption":"Comunicaci\u00f3n Leitat"},"sameAs":["https:\/\/leitat.org"],"url":"https:\/\/leitat.org\/en\/blog\/author\/comunica-wp\/"}]}},"_links":{"self":[{"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/posts\/59994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/comments?post=59994"}],"version-history":[{"count":1,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/posts\/59994\/revisions"}],"predecessor-version":[{"id":60037,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/posts\/59994\/revisions\/60037"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/media\/47191"}],"wp:attachment":[{"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/media?parent=59994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/categories?post=59994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/tags?post=59994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}